Claims
- 1. A process of alleviating anxiety which comprises systemically administering to an anxious individual a pharmaceutical composition in dosage unit form comprising per dosage from about 15 to about 350 mg of a member selected from the group consisting of a compound of the formula: ##STR14## wherein n is the integer 1, 2 or 3, R is a member selected from the group consisting of hydrogen and loweralkyl, R.sub.1 is a member selected from the group consisting of loweralkyl and benzyl, R.sub.2 is a member selected from the group consisting of hydrogen and loweralkyl, and Ar is a member selected from the group consisting of phenyl, halophenyl, loweralkylphenyl, loweralkoxyphenyl, trifluoromethylphenyl, nitrophenyl, cyanophenyl, methylithiophenyl, loweralkylcarbonyl-phenyl and benzyloxyphenyl, provided that when said n is 2 or 3, then said R is hydrogen and said R.sub.1 is loweralkyl, and the therapeutically active acid addition salts thereof in admixture with a pharmaceutical carrier.
- 2. A process of alleviating anxiety which comprises systemically administering to an anxious individual a pharmaceutical composition in dosage unit form comprising per dosage unit from about 15 to about 350 mg of a member selected from the group consisting of a compound of the formula: ##STR15## wherein Ar.sup.1 is a member selected from the group consisting of halophenyl, loweralkylphenyl, nitrophenyl and trifluoromethylphenyl, and the therapeutically active acid addition salts thereof in admixture with a pharmaceutical carrier.
- 3. A process of alleviating anxiety which comprises systemically administering to an anxious individual a pharmaceutical composition in dosage unit form comprising per dosage unit from about 15 to about 350 mg of a member selected from the group consisting of 1-m-chlorophenyl-3-(1-methyl-2-pyrrolidylidene)urea and the therapeutically active acid addition salts thereof in admixture with a pharmaceutical carrier.
- 4. A process of alleviating anxiety which comprises systemically administering to an anxious individual a pharmaceutical composition in dosage unit form comprising per dosage unit from about 15 to about 350 mg of a member selected from the group consisting of 1-p-nitrophenyl-3-(1-methyl-2-pyrrolidylidene)urea and the therapeutically active acid addition salts thereof in admixture with a pharmaceutical carrier.
- 5. A pharmaceutical composition for alleviating anxiety in dosage unit form comprising per dosage unit from about 15 to about 350 mg of a member selected from the group consisting of 1-m-chlorophenyl-3-(1-methyl-2-pyrrolidylidene)urea and the therapeutically active acid addition salts thereof in admixture with a pharmaceutically acceptable carrier.
- 6. The composition of claim 5 wherein said dosage unit is a tablet.
- 7. The composition of claim 5 wherein said dosage unit is a capsule.
CROSS-REFERENCE TO RELATED APPLICATION:
This is a divisional application of my co-pending application Ser. No. 499,706, filed on Aug. 22, 1974, now abandoned, which in turn is a continuation-in-part of application Ser. No. 335,845, filed Feb. 26, 1973, now abandoned, which in turn is a continuation-in-part of application Ser. No. 235,816, filed Mar. 17, 1972, abandoned.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
3717648 |
Diana |
Feb 1973 |
|
Divisions (1)
|
Number |
Date |
Country |
Parent |
499706 |
Aug 1974 |
|
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
335845 |
Feb 1973 |
|
Parent |
235816 |
Mar 1972 |
|